| 2006-12 |
JapanBridge Inc. was established in the United States with investment from MPM Capital and Itochu Corporation as a preparatory base for our pharmaceutical development business. |
| 2006-12 |
Established JapanBridge Inc. in the United States as a preparatory base for our pharmaceutical development business, funded by MPM Capital and Itochu Corporation. |
| 2007-01 |
Bajakara Co., Ltd. (now our company) was established. |
| 2007-01 |
Established Bajakara Co., Ltd. (now our company). |
| 2008-04 |
JapanBridge Inc. acquired our company and transferred its pharmaceutical development business from JapanBridge Inc.; the company name was changed to JapanBridge Co., Ltd. (now our company). |
| 2008-04 |
JapanBridge Inc. acquired our company and transferred its pharmaceutical development business: the company was renamed JapanBridge Co., Ltd. (now our company). |
| 2008-05 |
Exclusive development and sales rights for SP-01 in Japan, Taiwan, Singapore, Malaysia, and China (including Hong Kong and Macau) were introduced from Strakan International Ltd. (now Kyowa Kirin Services Limited) (UK). The Japanese rights were returned to Strakan International Ltd. in January 2011. |
| 2008-05 |
Acquired exclusive development and sales rights for SP-01 in Japan, Taiwan, Singapore, Malaysia, and China (including Hong Kong and Macau) from Strakan International Ltd. (now Kyowa Kirin Services Limited) (UK). The Japanese rights were returned to Strakan International Ltd. in January 2011. |
| 2008-09 |
The company name was changed to Solisia Pharma Inc. |
| 2008-09 |
Renamed to Solagia Pharma Co., Ltd. |
| 2010-02 |
Exclusive development and sales rights for SP-01 in Taiwan, Hong Kong, Singapore, and Malaysia were transferred to Kyowa Kirin Co., Ltd. (now Kyowa Kirin Co., Ltd.). |
| 2010-02 |
Transferred exclusive development and sales rights for SP-01 in Taiwan, Hong Kong, Singapore, and Malaysia to Kyowa Kirin Co., Ltd. (now Kyowa Kirin Co., Ltd.). |
| 2011-03 |
Exclusive development and sales rights for SP-02 in the Asia-Pacific region were introduced from ZIOPHARM Oncology, Inc. (now Alaunos Therapeutics) (USA). |
| 2011-03 |
Acquired exclusive development and sales rights for SP-02 in the Asia-Pacific region from ZIOPHARM Oncology, Inc. (now Alaunos Therapeutics) (USA). |
| 2011-12 |
A representative office was established in Beijing for development activities in China. |
| 2011-12 |
Established a representative office in Beijing for development activities in China. |
| 2014-07 |
Exclusive development and sales rights for SP-02 in the United States and European countries were introduced from ZIOPHARM Oncology, Inc. (now Alaunos Therapeutics) (USA). |
| 2014-07 |
Acquired exclusive development and sales rights for SP-02 in the United States and European countries from ZIOPHARM Oncology, Inc. (now Alaunos Therapeutics) (USA). |
| 2014-12 |
A subsidiary, Solasia Medical Information Consulting (Shanghai) Co., Ltd., was established in Shanghai, China. |
| 2014-12 |
Established a subsidiary, Solasia Medical Information Consulting (Shanghai) Co., Ltd., in Shanghai, China. |
| 2015-03 |
Exclusive development and sales rights for SP-03 in Japan and China were introduced from Camurus AB (Sweden). |
| 2015-03 |
Acquired exclusive development and sales rights for SP-03 in Japan and China from Camurus AB (Sweden). |
| 2015-11 |
Exclusive sales rights for SP-01 in China (excluding Beijing, Shanghai, Guangzhou, Hong Kong, and Macau) were transferred to Lee’s Pharmaceutical (HK) Limited. |
| 2015-11 |
Transferred exclusive sales rights for SP-01 in China (excluding Beijing, Shanghai, Guangzhou, Hong Kong, and Macau) to Lee’s Pharmaceutical (HK) Limited. |
| 2016-11 |
Sales rights for SP-03 in Japan were transferred to Meiji Seika Pharma Co., Ltd. |
| 2016-11 |
Transferred sales rights for SP-03 in Japan to Meiji Seika Pharma Co., Ltd. |
| 2017-02 |
Exclusive sales rights for SP-03 in China (excluding Beijing, Shanghai, and Guangzhou) were transferred to Lee’s Pharma (HK) Limited. |
| 2017-02 |
Transferred exclusive sales rights for SP-03 in China (excluding Beijing, Shanghai, and Guangzhou) to Lee’s Pharma (HK) Limited. |
| 2017-03 |
The company was listed on the Tokyo Stock Exchange Mothers. |
| 2017-03 |
Listed shares on the Tokyo Stock Exchange Mothers market. |
| 2017-07 |
Approval for manufacturing and sales of the medical device SP-03 in Japan was obtained. |
| 2017-07 |
Obtained approval for manufacturing and marketing of SP-03 as a medical device in Japan. |
| 2017-11 |
Exclusive development and sales rights for SP-04 in Japan, China, South Korea, Taiwan, Hong Kong, and Macau were introduced from PledPharma AB (now Egetis Therapeutics AB) (Sweden). |
| 2017-11 |
Acquired exclusive development and sales rights for SP-04 in Japan, China, South Korea, Taiwan, Hong Kong, and Macau from PledPharma AB (now Egetis Therapeutics AB) (Sweden). |
| 2018-05 |
The Episil® oral liquid (SP-03) was launched in Japan. |
| 2018-05 |
Released Episil® oral liquid (SP-03) in Japan. |
| 2018-07 |
Approval for the new drug SP-01 in China was obtained. |
| 2018-07 |
Obtained new drug approval for SP-01 in China. |
| 2018-08 |
Introduction of exclusive development sales rights for SP-03 in South Korea from Camurus AB. |
| 2018-08 |
Derivation of exclusive sales rights for SP-02 in eight South American countries to HB Human BioScience SAS (Colombia). |
| 2018-08 |
Acquired exclusive development and sales rights for SP-03 in South Korea from Camurus AB. |
| 2018-08 |
Transferred exclusive sales rights for SP-02 in eight South American countries to HB Human BioScience SAS (Colombia). |
| 2019-02 |
Obtained medical device approval for SP-03 in China. |
| 2019-02 |
Obtained medical device approval for product SP-03 in China. |
| 2019-03 |
Released Sancuso® (SP-01, Chinese product name '善可舒®') in China. |
| 2019-03 |
Released Sancuso® (SP-01, Chinese product name '善可舒®') in China. |
| 2019-07 |
Released episil® oral liquid (SP-03, Chinese product name '益普舒®') in China. |
| 2019-07 |
Released episil® oral liquid (SP-03, Chinese product name '益普舒®') in China. |
| 2019-10 |
Obtained medical device approval for SP-03 in South Korea. |
| 2019-10 |
Obtained medical device approval for product SP-03 in Korea. |
| 2019-12 |
Derivation of exclusive sales rights for SP-04 in Japan to Maruh Co., Ltd. |
| 2019-12 |
Transferred exclusive sales rights for product SP-04 in Japan to Marho Co., Ltd. |
| 2020-01 |
Derivation of exclusive sales rights for SP-03 in South Korea to Synex Co. |
| 2020-01 |
Transferred exclusive sales rights for product SP-03 in Korea to Synex Co. |
| 2020-08 |
Introduction of exclusive development sales rights for SP-05 in Japan from Isofol Medical AB (Sweden). |
| 2020-08 |
Introduced exclusive development and sales rights for product SP-05 in Japan from Isofol Medical AB (Sweden). |
| 2020-09 |
Released episil® oral liquid (SP-03) in South Korea. |
| 2020-09 |
Released episil® oral liquid (SP-03) in Korea. |
| 2021-10 |
Derivation of commercialization rights for SP-02 in Japan to Nippon Kiyaku Co., Ltd. |
| 2021-10 |
Transferred commercialization rights for product SP-02 in Japan to Nihon Kiyaku Co., Ltd. |
| 2022-04 |
Changed to the Growth Market of the Tokyo Stock Exchange. |
| 2022-04 |
Changed to the Growth Market of the Tokyo Stock Exchange. |
| 2022-07 |
Obtained exclusive worldwide manufacturing and sales rights for SP-03 from Camurus AB. |
| 2022-07 |
Obtained exclusive worldwide manufacturing and sales rights for product SP-03 from Camurus AB. |
| 2022-08 |
Sales of SP-01 and SP-03 started across China by Lee’s Pharmaceutical (HK) Limited. |
| 2022-08 |
Sales of Darvias® 135 mg IV infusion (generic name: Darinaparin, development code SP-02) started in Japan. |
| 2022-08 |
Started sales of products SP-01 and SP-03 throughout China through Lee’s Pharmaceutical (HK) Limited. |
| 2022-08 |
Sold Darvias® 135mg IV infusion (generic name: Darinaparin, development code SP-02) in Japan. |
| 2024-02 |
The source of exclusive development sales rights for Sancuso® in China and elsewhere changed to Kyowa Kirin International UK NewCo Limited. |
| 2024-02 |
The exclusive development and sales rights provider for Sancuso® in China and elsewhere changed to Kyowa Kirin International UK NewCo Limited. |
| 2024-12 |
Derivation of exclusive sales rights for SP-03 episil® in China to GenSci Singapore Pte. Ltd. (subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd.) and its group companies. |
| 2024-12 |
Transferred exclusive sales rights for SP-03 episil® in China to GenSci Singapore Pte. Ltd. (subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd.) and its group companies. |
| 2025-08 |
Derivation of exclusive sales rights for SP-03 episil® in Brazil to Daiichi Sankyo Brasil Farmacêutica Ltda. (100% subsidiary of Daiichi Sankyo Co., Ltd.). |
| 2025-08 |
Transferred exclusive sales rights for SP-03 episil® in Brazil to Daiichi Sankyo Brasil Farmacêutica Ltda. (100% subsidiary of Daiichi Sankyo Co., Ltd.). |
| 2026-01 |
Derivation of exclusive sales rights for SP-01 Sancuso® in the China region (mainland China, Hong Kong, Macau, Taiwan) to MAAB Pharma Limited. |
| 2026-01 |
Transferred exclusive sales rights for SP-01 Sancuso® in China (mainland China, Hong Kong, Macau, Taiwan) to MAAB Pharma Limited. |
